Brand-Name Medication Costs (Without Insurance): Semaglutide (Wegovy/Ozempic): List Price: $1,349 per month With Manufacturer Coupon: May reduce to $25/month with commercial insurance (not available for Medicare/Medicaid or cash-pay patients) Average With Insurance: $25-$300 per month depending on coverage Availability: Ongoing shortages affecting access Tirzepatide (Zepbound/Mounjaro): List Price: $1,069 per month With Manufacturer Coupon: May reduce to $25/month with commercial insurance (not available for Medicare/Medicaid or cash-pay patients) Average With Insurance: $25-$300 per month depending on coverage Availability: Better availability than semaglutide, though still limited Compounded Medication Costs: Compounded Semaglutide: TrimRx: $199/month with annual commitment Other Providers: $199-$599/month Insurance: Not covered HSA/FSA: Usually eligible Savings vs Brand-Name: $1,150/month ($13,800/year) Compounded Tirzepatide: TrimRx: $349/month with annual commitment Other Providers: $349-$699/month Insurance: Not covered HSA/FSA: Usually eligible Savings vs Brand-Name: $720/month ($8,640/year) Annual Cost Comparison: Cost vs Effectiveness Analysis: Compounded Options: For the $150/month price difference ($1,800/year) between compounded semaglutide and tirzepatide: You get approximately 7.6% more weight loss on average For a 250-pound person, thats about 19 additional pounds lost Cost per additional pound lost: ~$95 Is the Extra Cost Worth It

Melanotan IIs libido effects typically peak 2-6 hours after injection, making evening timing optimal for nighttime intimacy
"I have replaced the serotonin [and dopamine] and happiness I would get from eating all those foods with hobbies in my real life" such as weightlifting, knitting, playing video games and, most recently, running
The expanded approval was based on data from the Phase III EoE KIDS trial, where 66% of children who received the higher dose Dupixent at tiered dosing regimens experienced histological disease remission after 16 weeks of treatment, compared to just 3% in the placebo group, per the press release
On one hand, we have the most effective and potentially scalable intervention to the most common chronic disease in the world